The INTERfaces program will train 14 ESRs within an EID network jointly designed by European academic and industry partners in innovative research projects dedicated to developing clean bioprocesses for the production of chemicals. The assembly of biocatalysts to reaction sequences allows avoiding steps for isolation and purification of intermediates and thus a significant improvement of the environmental footprint of catalytic processes. The main goal of INTERfaces is the extension of this concept towards multi-step biocatalytic reactions in immobilized form. These “Heterogeneous Biocatalytic Reaction Cascades” will greatly facilitate re-use of the catalysts and further simplify downstream-processing. INTERfaces combines material science and protein engineering to design tailored enzymes and (bio-based) materials that will complement each other to obtain optimized heterogeneous biocatalysts. These tools will be applied to solve synthetic challenges in the use of two biobased monomers as starting materials to synthesize products for application fields like antioxidants and biopolymers. Process optimization and up-scale in industry will reveal key factors for synthetic utilization of the biocatalysts. INTERfaces emphasizes particularly the engineering of the designed cascades in solid phase. This includes the design of reactors, use of computational modeling tools, application of the right operational modes, and reaction medium needed for desired space-time-yields and product titers. Commercial relevant processes will be up-scaled together with industry for technical implementation. 13 Non-academic partners ranging from high-tech SMEs to large producing companies and 9 academic institutions offer an intersectoral and interdisciplinary environment to provide 14 Ph.D. candidates with outstanding employability profiles for the European Biotech Sector. Dedicated workshops and well-balanced supervisory team aim at increasing the gender diversity in biotech research.

Increased demand for high-quality healthcare for our aging population means that medical device design must satisfy multiple requirements for enhanced biocompatibility, anti-bacterial resistance, manipulation of proteins and improved physical properties. The use of micro/nano structures integral to the surface of a device is a novel way to uniformly tune and control these properties. Polymer materials are ubiquitous in medical devices: in Europe alone, this sector includes 27,000 companies employing 675,000 people with an annual turnover of €110 billion. Precision processing of polymers with micro/nano structures is critical to developing high value-added medical devices. Our ETN focuses on surface integrity issues when micro/nano processing polymers for high performance medical devices. We will develop micro/nano-scale precision manufacturing processes, specifically moulding and forming, and additive and subtractive manufacturing, aimed at 6 classes of medical devices that have particular industry-defined requirements. A strategy to design surface micro/nano structures that provide required functionality for these devices will be established. The surface integrity of these materials and devices will be studied at a fundamental level and correlated with functionality, allowing for optimising the efficacy and performance of the medical devices. Our training will ensure that 12 outstanding ESRs become experts in design and the precision micro/nano processing of polymers for medical devices, thereby improving their career prospects. Our ESRs will undertake interdisciplinary and intersectoral research on polymer micro/nano processing for medical applications and obtain work experience with international industry. They will receive specialised technical training and transferable skills structured around state-of-the-art individual research projects that will provide them with pathways to engineering and manufacturing careers in Europe’s world-leading industry.

Compared to the pace of innovation in electronic consumer products, the pace of innovation for medical devices is lagging behind. It is the overarching objective of Moore4Medical to accelerate innovation in electronic medical devices. Moore4Medical emerging medical applications that offer significant new opportunities for the ECS industry including: active implantable devices (bioelectronic medicines), organ-on-chip, drug adherence monitoring, smart ultrasound, radiation free interventions and continuous monitoring. The new technologies will help fighting the increasing cost of healthcare by: reducing the need for hospitalization, helping the development of personalized therapies, and realizing intelligent point-of-care diagnostic tools. Moore4Medical will bring together 68 specialists from 12 countries who will develop open technology platforms for these emerging fields to help them bridge “the Valley of Death” in shorter time and at lower cost. Open technology platforms used by multiple users for multiple applications with the prospect of medium to high volume markets are an attractive proposition for the European ECS industry. The combination of typical MedTech applications with an ECS style platform approach will enhance the competitiveness for the emerging medical domains addressed in Moore4Medical. With value and IP moving from the technology level towards applications and solutions, defragmentation and open technology platforms will be key in acquiring and maintaining a premier position for Europe in the forefront of affordable healthcare

LINkS will change the paradigm of the self-organization of the intracellular living matter by demonstrating the existence of Long-range ElectroDynamic Interactions (LEDIs) between proteins. LEDIs may act as a long distance protein-protein attractive mechanism expanding above several hundred of Angströms that could explain the high spatial organization and coordination of biomolecular reactions; responsible for the transmission of information in cells. LEDIs result from condensation phenomenon, characterized by the emerging of the mode of lowest frequency; expected in the TeraHertz (THz) frequency band. However, to date, LEDIs have eluded detection, partly because previous theoretical predictions were incorrect, but also because performing THz spectroscopy in aqueous media is a well-known technological roadblock not yet overcome. LINkS will develop a breakthrough lab-on-chip THz biosensor technology to investigate LEDIs between proteins, from in-vitro to in-vivo. No competing or alternative technology exist yet. To this end, LINkS consortium gathers interdisciplinary expertise including theoretical biophysics, cell biology, nanotechnology and microfluidic engineering. Three academic partners and two SMEs, from four European countries will work in strong collaboration, across the traditional boundaries of their disciplines, to develop a disruptive lab-on-chip THz biosensor able to investigate LEDIs in the real complexity of biological systems. LINkS technology will effectively address proteomic analysis and related markets for the benefit of society as a whole. In the long-term, its ramifications will have significant benefits for drug discovery, biomarker identification and associated personalised therapies, and for understanding the influence of electromagnetic fields on living organisms; thus opening up new fields of research in medicine and biology.

PHOENIX aims to revolutionise biomedical research by developing the next generation human-based Organs-on-chips (OoC). OoC is a promising technology potentially able to outperform conventional preclinical models in providing patho-physiologically relevant setting for investigating human diseases, thus tackling the limited translational value of animal testing. OoC wide adoption is currently hampered by poor maturation of cellular models and shortage of non-destructive readout methods. PHOENIX will take current OoC platforms to the next level, overcoming such limitations by integration of core technologies already validated by the Consortium, namely Electric Recording (3dMEA), Force Sensing (3dFORCE) and Mechanical Stimulation (3dMECH). Two platforms will be developed: i) μHeart, to model functional cardiac tissues, and ii) μNMC to model neuro-muscular circuits. PHOENIX ecosystem will be completed by satellite products and qualified against specific contexts of use in clinically and industrially relevant environments. PHOENIX potential will be showcased with two genetic pathologies as demonstrators: LMNA-cardiomyopathies and Freidreich’s Ataxia, conditions in which electrical instability and mechanical impairment play important roles. For each platform, two versions will be released (Base and Pro), addressing the need of identified customer segments (research labs and Pharma/Biotech). In line with the 3Rs, PHOENIX platforms represent the ideal clinically relevant tools to test drugs and gene therapies, leading to faster/safer development processes, reducing the need for animal testing. Robust dissemination, exploitation and communication activities will address both key stakeholders (OoC players, end-users, end-beneficiaries and regulatory bodies) and society at large, fostering acceptance, adoption, economic viability and regulatory compliance. PHOENIX will last 4 years with a Consortium comprising 9 partners (Academic, SMEs and LEs) from 4 EU Countries.